Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Angiology. 2014 Mar; 65(3):190-7.A

Abstract

We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and utility. Resource use data were sourced from the literature and sensitivity analyses were undertaken. Naftidrofuryl oxalate is more effective and less costly than cilostazol and pentoxifylline and has an estimated cost per quality-adjusted life year gained of around £6070 compared to no vasoactive drug. The analysis uses effectiveness evidence from a network meta-analysis. In contrast to previous guidelines recommending cilostazol, the analysis suggests that naftidrofuryl oxalate is the only vasoactive drug for PAD which is likely to be cost-effective.

Authors+Show Affiliations

1School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23378195

Citation

Meng, Yang, et al. "Cost-effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease." Angiology, vol. 65, no. 3, 2014, pp. 190-7.
Meng Y, Squires H, Stevens JW, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014;65(3):190-7.
Meng, Y., Squires, H., Stevens, J. W., Simpson, E., Harnan, S., Thomas, S., Michaels, J., Stansby, G., & O'Donnell, M. E. (2014). Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology, 65(3), 190-7. https://doi.org/10.1177/0003319712474335
Meng Y, et al. Cost-effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology. 2014;65(3):190-7. PubMed PMID: 23378195.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. AU - Meng,Yang, AU - Squires,Hazel, AU - Stevens,John W, AU - Simpson,Emma, AU - Harnan,Sue, AU - Thomas,Steve, AU - Michaels,Jonathan, AU - Stansby,Gerard, AU - O'Donnell,Mark E, Y1 - 2013/01/31/ PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2014/3/26/medline KW - cilostazol KW - cost-effectiveness analysis KW - intermittent claudication KW - naftidrofuryl oxalate KW - pentoxifylline KW - peripheral arterial disease SP - 190 EP - 7 JF - Angiology JO - Angiology VL - 65 IS - 3 N2 - We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and utility. Resource use data were sourced from the literature and sensitivity analyses were undertaken. Naftidrofuryl oxalate is more effective and less costly than cilostazol and pentoxifylline and has an estimated cost per quality-adjusted life year gained of around £6070 compared to no vasoactive drug. The analysis uses effectiveness evidence from a network meta-analysis. In contrast to previous guidelines recommending cilostazol, the analysis suggests that naftidrofuryl oxalate is the only vasoactive drug for PAD which is likely to be cost-effective. SN - 1940-1574 UR - https://www.unboundmedicine.com/medline/citation/23378195/Cost_effectiveness_of_cilostazol_naftidrofuryl_oxalate_and_pentoxifylline_for_the_treatment_of_intermittent_claudication_in_people_with_peripheral_arterial_disease_ L2 - http://journals.sagepub.com/doi/full/10.1177/0003319712474335?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -